Tag Archives: analyst

Here’s the best place to put your money in health care during the 2020 debate season: Top analyst

Investors should put their money in small- to mid-cap biotech stocks as rhetoric about changing the U.S. health-care system ramps up during the Democratic primary debate season, Jefferies analyst Michael Yee said Friday. “The big biotechs have to buy the big and small biotechs, and that’s where most [health-care] investors have been playing,” Yee said… Read More »

‘Old guard’ generics players yield U.S. lead to Indian up-and-comers: analyst

The U.S. generics world has changed. Starting from around late 2018 to early 2019, traditional generics bigwigs Teva, Mylan, Novartis’ Sandoz, Amneal and Endo have lost out to a group of six competitors that include Indian drugmakers Aurobindo Pharma, Lupin, Dr. Reddy’s, Sun Pharma, Cipla and Canada’s Apotex in terms of weekly total prescriptions, Evercore… Read More »

With safety data, Bayer could challenge Erleada, Xtandi in prostate cancer: analyst

For years, Johnson & Johnson and the Pfizer-Astellas team have been the only players in their class of prostate-cancer fighters. But Bayer is waiting in the wings, and stellar new safety data could make it a threat. The German drugmaker trumpeted phase 3 data Thursday on its androgen receptor antagonist candidate, darolutamide, showing that the drug… Read More »